Using advanced CT imaging to improve lung cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of photon counting computed tomography (PCCT) and its spectral information in evaluating patients suspected of having lung cancer. It aims to compare the diagnostic accuracy of PCCT with conventional CT and PET imaging for tumor staging. Patients will be randomized to receive readings with or without spectral information, allowing researchers to assess the impact on follow-up examinations and the classification of findings. The study will also evaluate the need for additional work-ups based on the findings reported.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients suspected of lung cancer refered to Copenhagen University Hospital as per the guidelines from the danish national health authorities from either the general practitioner or from the department of pulmonology.
* Informed consent

Exclusion Criteria:

* Patients who cannot tolerate intravenous iodinated contrast
* Already verified lung cancer from another institution
* Comorbidities that exclude the patient from receiving treatment
* Lack of reference standard in the form of either histology or follow-up
* Known extrapulmonary malignancy
* Technical limitations within the scans/reconstructions
* other

Pr. the 29th of September included 433 participants.

Where it's running

• Copenhagen University Hospital Herlev
  Herlev, Capital Region, Denmark Recruiting

Study contacts

• Principal investigator: Michael B Andersen, PhD — Copenhagen University Hospital at Herlev
• Study coordinator: Michael B Andersen, PhD
• Email: michael.brun.andersen@regionh.dk
• Phone: 38 68 38 68

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enhanced COPD care for people being checked for lung cancer

  This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.

  Recruiting Region of Southern Denmark · Vejle · NCT07543601

• MK-1084 combined with other therapies for advanced non-squamous non-small cell lung cancer

  This trial tests whether MK-1084 given with other anti-cancer drugs can shrink tumors in people with advanced or metastatic non-squamous NSCLC who have a KRAS G12C mutation and have progressed after prior platinum chemotherapy and PD-(L)1 therapy.

  Recruiting at 29 sites Phase 1/2 Merck Sharp & Dohme LLC · Clermont, Florida and 28 other locations · NCT07286149

• Low-dose intestinal radiation plus immunotherapy for immune-resistant metastatic solid cancers

  This trial tests whether giving small doses of radiation to the intestine together with PD‑1/PD‑L1 immunotherapy can help people whose metastatic solid tumors have stopped responding to checkpoint inhibitors.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07071103

• Evaluating a new imaging technique for lung cancer diagnosis

  This study is testing a new imaging technique during lung procedures to see if it helps doctors diagnose lung cancer more accurately in patients with suspicious lung lesions.

  Recruiting at 5 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · New York, New York and 4 other locations · NCT06079970

• Understanding response to stereotactic body radiotherapy in early-stage lung cancer

  This study is trying to understand why some people with early-stage lung cancer respond better to a specific type of radiation treatment than others, to help improve future treatments.

  Recruiting at 2 sites European Institute of Oncology · Milan, Italy and 1 other locations · NCT05974475

• Combining sintilimab, bevacizumab, and chemotherapy for lung cancer treatment before surgery

  This study is testing a new treatment that combines two medications and chemotherapy before surgery to see if it helps people with advanced lung cancer.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT04973293

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.